![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Characterization of HCV Resistance From a 3-Day Monotherapy Study
of GS-9857, a Novel Pangenotypic NS3/4A Protease Inhibitor
|
|
|
Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco
Eric Lawitz,1 Hadas Dvory-Sobol,2 Jenny C. Yang,2 Luisa M. Stamm,2 James G. Taylor,2 Diana M. Brainard,2 Michael D. Miller,2 Hongmei Mo,2 Maribel Rodriguez-Torres3
1Alamo Medical Research, San Antonio, TX; 2Gilead Sciences, Inc., Foster City, CA; 3Fundación de Investigación, Rio Pedras, Puerto Rico
![AASLD1.gif](../images/121815/121815-5/AASLD1.gif)
![AASLD2.gif](../images/121815/121815-5/AASLD2.gif)
![AASLD3.gif](../images/121815/121815-5/AASLD3.gif)
![AASLD4.gif](../images/121815/121815-5/AASLD4.gif)
![AASLD5.gif](../images/121815/121815-5/AASLD5.gif)
![AASLD6.gif](../images/121815/121815-5/AASLD6.gif)
![AASLD7.gif](../images/121815/121815-5/AASLD7.gif)
![AASLD8.gif](../images/121815/121815-5/AASLD8.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|